Evidence map›Paper›PMID 39065620›Full record

ReviewPharmaceutics2024

Exploring the Biomedical Frontiers of Plant-Derived Nanoparticles: Synthesis and Biological Reactions.

Selvaraj Barathi, Srinivasan Ramalingam, Gopinath Krishnasamy, Jintae Lee

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Selvaraj BarathiSchool of Chemical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea.ORCID 0000-0003-0957-7263
Srinivasan RamalingamDepartment of Horticulture & Life Science, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Gopinath KrishnasamyInstitute of Biomedicine, University of Turku, FI-20520 Turku, Finland.ORCID 0000-0003-0063-1905
Jintae LeeSchool of Chemical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea.ORCID 0000-0003-1383-1682

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As contemporary technology advances, scientists are striving to identify new approaches to managing several diseases. Compared to the more popular physiochemical synthesis, the plant-derived combination of metallic nanoparticles using plant secondary metabolites as a precursor has a number of benefits, including low expenses, low energy consumption, biocompatibility, and medicinal usefulness. This study intends to explore the impacts of using plant-derived synthetic materials including metallic nanoparticles (NPs), emphasizing the benefits of their broad use in next-generation treatments for cancer, diabetes, Alzheimer's, and vector diseases. This comprehensive analysis investigates the potential of plant-derived remedies for diseases and looks at cutting-edge nanoformulation techniques aimed at addressing the function of the nanoparticles that accompany these organic substances. The purpose of the current review is to determine how plant extracts contribute to the synthesis of Silver nanoparticles (AgNPs), Gold nanoparticles (GtNPs), and platinum nanoparticles (PtNPs). It provides an overview of the many phytocompounds and their functions in biomedicine, including antibacterial, antioxidant, anticancer, and anti-inflammatory properties. Furthermore, this study placed a special focus on a range of applications, including drug delivery systems, diagnostics and therapy, the present benefits of nanoparticles (NPs), their biomedical uses in medical technology, and their toxicities.

Indexed as

biomedicalcancerdrug delivery systemnanotechnologyplant extractstoxicity

Identifiers

PMID39065620
PMCPMC11279729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.